Knowledge Hub

Global Alpha-1 Antitrypsin Drugs Market to grow at a CAGR of 35.42% during the period 2016-2020.

Press Release   •   May 09, 2016 08:50 EDT

"The Report Global Alpha-1 Antitrypsin Drugs Market 2016-2020 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Description

About Alpha-1 antitrypsin Drugs

Alpha-1 antitrypsin, also known as an alpha-1 protease inhibitor (A1PI), is a glycoprotein produced in the liver that helps in the inactivation of enzymes such as elastase, which break down proteins during inflammation induced by some injury. The decline in alpha-1 antitrypsin levels in the blood results in a rare genetic condition known as alpha-1 antitrypsin deficiency (AATD), which leads to the development of respiratory and liver diseases, and severe skin infections. The disease is passed on from parents to an offspring through mutated genes. Augmentation therapy using drugs derived from human plasma helps in maintaining levels of alpha-1 antitrypsin in the blood, helping in remission of the condition.

Technavios analysts forecast the Global Alpha-1 Antitrypsin Drugs Market to grow at a CAGR of 35.42% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global alpha-1 antitrypsin drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded drugs and off-label drugs used for the symptomatic treatment of diseases occurring due to alpha-1 antitrypsin deficiency and other disorders.

The market is divided into the following segments based on geography:

Americas

APAC

EMEA

Technavio's report, Global Alpha-1 Antitrypsin Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Download Free Sample of this Report

Key vendors

Baxter International

CSL Behring

Grifols

Kamada

Other prominent vendors

Abeona Therapeutics

Alnylam Pharmaceuticals

Applied Genetic Technologies

Arrowhead Research

Baxalta

Biogen

Chiesi

Curaxys

Laboratoire franais du Fractionnement et des Biotechnologies

ProBioGen

ProMetic Life Sciences

Market driver

Improved diagnosis of alpha-1 antitrypsin deficiency (AATD)

For a full, detailed list, view our report

Market challenge

Limited plasma fractionation capacity

For a full, detailed list, view our report

Market trend

Increasing awareness about therapy

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?